Standpoint Research Starts Coherus Biosciences (CHRS) at Buy

November 25, 2016 10:06 AM EST
Get Alerts CHRS Hot Sheet
Price: $26.05 -0.19%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade CHRS Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Standpoint Research initiates coverage on Coherus Biosciences (NASDAQ: CHRS) with a Buy rating and a price target of $40.00.

For an analyst ratings summary and ratings history on Coherus Biosciences click here. For more ratings news on Coherus Biosciences click here.

Shares of Coherus Biosciences closed at $28.10 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

New Coverage

Related Entities

Standpoint Research

Add Your Comment